BETHESDA, Md. -- A federal advisory committee recommended that the Food and Drug Administration give physicians more information about a study of the heart drug Cardura, but the divided panel could not agree on changing the drug's label.
The panel, assembled Thursday to consider a citizens' petition calling for a warning to be issued about Cardura, was divided on the interpretation of a federal study that had linked the drug to an increased incidence of congestive heart failure and stroke.
Brainerd Dispatch ©2013. All Rights Reserved.